CHICAGO, Oct. 7, 2019 /PRNewswire/ — The Chartis Group, a comprehensive healthcare advisory and analytics firm, has been selected as one of Modern Healthcare’s Top 25 “Best Places to Work in Healthcare” for 2019.
This annual award, now in its twelfth year, recognizes providers and suppliers throughout the healthcare industry that empower their employees to provide patients and customers with the best possible care, products and services. Results are based on employee responses to an employee engagement and satisfaction survey.
“We are thrilled to be recognized again this year as one of Modern Healthcare’s best places to work,” says Shannon Brownell, Chief Talent Officer of The Chartis Group. “At Chartis, we remain committed to fostering an environment in which talented professionals can have a meaningful impact on the healthcare industry, continuously grow as individuals, and experience the joy of working with fun, caring and inspiring colleagues.”
This is the fifth year that The Chartis Group has participated in the Best Places to Work program and the fifth year the firm has been ranked in the Top 25 suppliers.
About The Chartis Group
The Chartis Group® (Chartis) provides comprehensive advisory services and analytics to the healthcare industry. With an unparalleled depth of expertise in strategic planning, performance excellence, informatics and technology, and health analytics, Chartis helps leading academic medical centers, integrated delivery networks, children’s hospitals and healthcare service organizations achieve transformative results. Chartis has offices in Atlanta, Boston, Chicago, New York, Minneapolis and San Francisco. For more information, visit www.chartis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/the-chartis-group-named-one-of-the-top-25-best-places-to-work-in-healthcare-for-fifth-straight-year-300933051.html
SOURCE The Chartis Group
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="62px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
